Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin.
Thirty-one patients with advanced head and neck cancer were treated with 4'-epidoxorubicin. Three of 25 evaluable patients with squamous cell carcinoma and two of three with minor salivary gland carcinoma had partial remissions. Four patients received cumulative doses of 680-1270 mg/m2; none developed clinical heart failure.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010976:Platelet Count
D015251:Epirubicin; D004317:Doxorubicin